{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06345729",
            "orgStudyIdInfo": {
                "id": "1084-004"
            },
            "secondaryIdInfos": [
                {
                    "id": "MK-1084-004",
                    "type": "OTHER",
                    "domain": "Merck"
                },
                {
                    "id": "U1111-1296-8093",
                    "type": "OTHER",
                    "domain": "UTN"
                },
                {
                    "id": "2023-507776-42",
                    "type": "REGISTRY",
                    "domain": "EU CT"
                },
                {
                    "id": "jRCT2031240213",
                    "type": "REGISTRY",
                    "domain": "jRCT"
                }
            ],
            "organization": {
                "fullName": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) \u226550% (MK-1084-004)",
            "officialTitle": "A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Metastatic NSCLC With PD-L1 TPS \u226550%",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-mk-plus-pembrolizumab-mk-in-participants-with-kras-mutant-metastatic-non-small-cell-lung-cancer-nsclc-with-programmed-cell-death-ligand-pd-tumor-proportion-score-tps-mk"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2029-02-19",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2031-02-18",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-28",
            "studyFirstSubmitQcDate": "2024-03-28",
            "studyFirstPostDateStruct": {
                "date": "2024-04-03",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a study evaluating the efficacy and safety of MK-1084 with pembrolizumab as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) \u226550%. There are two primary study hypotheses:\n\nHypothesis 1: Combination of MK-1084 and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).\n\nHypothesis 2: Combination of MK-1084 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to overall survival (OS)."
        },
        "conditionsModule": {
            "conditions": [
                "Non-small Cell Lung Cancer"
            ],
            "keywords": [
                "Programmed Cell Death-1 (PD1, PD-1)",
                "Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)",
                "Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)",
                "Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 600,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "MK-1084 with Pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles and MK-1084 by oral tablets once daily until discontinuation criterion is met.",
                    "interventionNames": [
                        "Drug: MK-1084",
                        "Biological: Pembrolizumab"
                    ]
                },
                {
                    "label": "Placebo with Pembrolizumab",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles and placebo by oral tablets once daily until discontinuation criterion is met.",
                    "interventionNames": [
                        "Other: Placebo",
                        "Biological: Pembrolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "MK-1084",
                    "description": "Oral tablets",
                    "armGroupLabels": [
                        "MK-1084 with Pembrolizumab"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Oral tablets",
                    "armGroupLabels": [
                        "Placebo with Pembrolizumab"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Pembrolizumab",
                    "description": "IV infusion",
                    "armGroupLabels": [
                        "MK-1084 with Pembrolizumab",
                        "Placebo with Pembrolizumab"
                    ],
                    "otherNames": [
                        "MK-3475",
                        "KEYTRUDA \u00ae"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Progression-Free Survival (PFS)",
                    "description": "PFS is defined as the time from randomization until either documented disease progression per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or death due to any cause, whichever occurs first. PFS as determined by blinded independent central review (BICR) will be presented.",
                    "timeFrame": "Up to approximately 42 months"
                },
                {
                    "measure": "Overall Survival (OS)",
                    "description": "OS is defined as the time from randomization to death due to any cause.",
                    "timeFrame": "Up to approximately 56 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Objective Response Rate (ORR)",
                    "description": "ORR is defined as the percentage of participants with Complete Response or Partial Response per RECIST1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented.",
                    "timeFrame": "Up to approximately 42 months"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "For participants who demonstrate confirmed CR or PR per RECIST 1.1 as assessed by BICR, duration of response is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.",
                    "timeFrame": "Up to approximately 42 months"
                },
                {
                    "measure": "Number of Participants Who Experience One or More Adverse Event (AEs)",
                    "description": "An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experience an AE will be presented.",
                    "timeFrame": "Up to approximately 56 months"
                },
                {
                    "measure": "Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)",
                    "description": "An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinue study treatment due to an AE will be presented.",
                    "timeFrame": "Up to approximately 56 months"
                },
                {
                    "measure": "Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score",
                    "description": "The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions \"How would you rate your overall health during the past week?\" and \"How would you rate your overall quality of life during the past week?\" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in the score of EORTC QLQ-C30 Items 29 and 30 will be presented. Higher scores indicate a better overall health status.",
                    "timeFrame": "Baseline and Up to approximately 24 months"
                },
                {
                    "measure": "Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Physical Functioning (Items 1-5) Score",
                    "description": "The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). The change from baseline in the score of EORTC QLQ-C30 Items 1-5 will be presented. Higher scores indicate a better level of functioning.",
                    "timeFrame": "Baseline and Up to approximately 24 months"
                },
                {
                    "measure": "Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Role Functioning (Items 6 and 7) Score",
                    "description": "The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 2 questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). The change from baseline in the score of EORTC QLQ-C30 Items 6-7 will be presented. Higher scores indicate a better level of functioning.",
                    "timeFrame": "Baseline and Up to approximately 24 months"
                },
                {
                    "measure": "Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Dyspnea (Item 8) Score",
                    "description": "The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant response to the question \"Were you short of breath?\" is scored on a 4-point scale (1=Not at All to 4=Very Much). The change from baseline in the score of EORTC QLQ-C30 Item 8 will be presented. A higher score indicates a worse level of dyspnea.",
                    "timeFrame": "Baseline and Up to approximately 24 months"
                },
                {
                    "measure": "Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-C13) Cough (Item 31) Score",
                    "description": "The EORTC QLQ-C13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant response to the question \"Have you coughed?\" is scored on a 4-point scale (1=Not at All to 4=Very Much). The change from baseline in the score of EORTC QLQ-C13 Item 31 will be presented. A higher score indicates more frequent coughing.",
                    "timeFrame": "Baseline and Up to approximately 24 months"
                },
                {
                    "measure": "Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-LC13) Chest pain (Item 40) Score",
                    "description": "The EORTC QLQ-C13 is lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant response to the question \"Have you had pain in your chest?\" is scored on a 4-point scale (1=Not at All to 4=Very Much). The change from baseline in the score of EORTC QLQ-C13 Item 40 will be presented. A higher score indicates a worse level of chest pain.",
                    "timeFrame": "Baseline and Up to approximately 24 months"
                },
                {
                    "measure": "Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score",
                    "description": "TTD is defined as the time from baseline to the first onset of a \u226510-point negative change (decrease) from baseline in global health status (GHS) and quality of life (QoL) (EORTC QLQ-C30 Items 29 and 30) score. Participant responses to the questions \"How would you rate your overall health during the past week?\" and \"How would you rate your overall quality of life during the past week?\" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a \u226510 point negative change (decrease) from baseline in GHS and QoL, will be presented. A longer TTD indicates a better outcome.",
                    "timeFrame": "Baseline and Up to approximately 24 months"
                },
                {
                    "measure": "Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Physical Functioning (Items 1-5) Score",
                    "description": "TTD is defined as the time from baseline to the first onset of a \u226510-point negative change (decrease) from baseline in physical functioning (EORTC QLQ-C30 Items 1-5) score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a \u226510 point negative change (decrease) from baseline in physical functioning score, will be presented. A longer TTD indicates a better outcome.",
                    "timeFrame": "Baseline and Up to approximately 24 months"
                },
                {
                    "measure": "Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Role Functioning (Items 6 and 7) Score",
                    "description": "TTD is defined as the time from baseline to the first onset of a \u226510-point negative change (decrease) from baseline in role functioning (EORTC QLQ-C30 Items 6 and 7) score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 2 questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a \u226510 point negative change (decrease) from baseline in role functioning score, will be presented. A longer TTD indicates a better outcome.",
                    "timeFrame": "Baseline and Up to approximately 24 months"
                },
                {
                    "measure": "Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Dyspnea (Item 8) Score",
                    "description": "TTD is defined as the time from baseline to the first onset of a \u226510-point negative change (decrease) from baseline in dyspnea (EORTC QLQ-C30 Item 8) score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant response to the question \"Were you short of breath?\" is scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a \u226510 point negative change (decrease) from baseline in dyspnea score, will be presented. A longer TTD indicates a better outcome.",
                    "timeFrame": "Baseline and Up to approximately 24 months"
                },
                {
                    "measure": "Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-C13) Cough (Item 31) Score",
                    "description": "TTD is defined as the time from baseline to the first onset of a \u226510-point negative change (decrease) from baseline in cough (EORTC QLQ-C13 Item 31) score. The EORTC QLQ-C13 is lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant response to the question \"Have you coughed?\" is scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a \u226510 point negative change (decrease) from baseline in cough score, will be presented. A longer TTD indicates a better outcome.",
                    "timeFrame": "Baseline and Up to approximately 24 months"
                },
                {
                    "measure": "Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-C13) Chest pain (Item 40) Score",
                    "description": "TTD is defined as the time from baseline to the first onset of a \u226510-point negative change (decrease) from baseline in chest pain (EORTC QLQ-C13 Item 40) score. The EORTC QLQ-C13 is lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant response to the question \"Have you had pain in your chest?\" is scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a \u226510 point negative change (decrease) from baseline chest pain score, will be presented. A longer TTD indicates a better outcome.",
                    "timeFrame": "Baseline and Up to approximately 24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "The main inclusion and exclusion criteria include but are not limited to the following:\n\nInclusion Criteria:\n\n* Has a histologically or cytologically confirmed diagnosis of NSCLC\n* Has newly diagnosed Stage IV NSCLC by American Joint Committee on Cancer (AJCC) Staging Manual, Version 8\n* Has measurable disease based on RECIST 1.1\n* Has provided tumor tissue that demonstrates PD-L1 expression in \u226550% of tumor cells\n* Has provided tumor tissue that demonstrates presence of KRAS G12C mutation\n* Has life expectancy of at least 3 months\n* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days before randomization\n* For participant assigned male sex at birth: If capable of producing sperm, participant must agree to the following during the study treatment period and for at least 10 days after the last dose of oral intervention: Either be abstinent or must agree to use male condom plus additional contraceptive method.\n* For participant assigned female sex at birth: Either be a person of nonchildbearing potential (PONCBP) or must agree to follow contraceptive guidance during the study treatment period and for at least 10 days after the last dose of oral intervention and 120 days after the last dose of pembrolizumab. Must abstain from breastfeeding during the study intervention period and for at least 120 days after study intervention.\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART).\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization\n\nExclusion Criteria:\n\n* Diagnosis of small cell lung cancer\n* Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease\n* Has a known history of, or active, neurologic paraneoplastic syndrome\n* Has an active infection requiring systemic therapy\n* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QT interval corrected for heart rate by Fridericia's formula (QTcF) interval to \\>470 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention\n* Is considered a poor medical risk due to a serious, uncontrolled medical disorder or nonmalignant systemic disease. Examples include, but are not limited to, uncontrolled major seizure disorder, unstable spinal cord compression, or superior vena cava syndrome.\n* Has one or more of the following ophthalmological findings/conditions: intraocular diagnosis of central serous retinopathy, retinal vein occlusion, or retinal artery occlusion, diagnosis of retinal degenerative disease pressure \\>21 mm Hg and/or any diagnosis of glaucoma\n* Is unable to swallow orally administered medication, or has a gastrointestinal disorder affecting absorption (eg, gastrectomy, partial bowel obstruction, or malabsorption)\n* Received prior systemic anticancer therapy for their metastatic NSCLC\n* Received prior therapy with an anti-programmed cell death-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor within 12 months before diagnosis of metastatic NSCLC\n* Has received radiotherapy within 2 weeks of start of study intervention\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.\n* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration\n* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention\n* Active autoimmune disease that has required systemic treatment in the past 2 years\n* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease\n* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease\n* History of allogeneic tissue/solid organ transplant\n* Has not fully recovered from any effects of major surgical procedure. Surgical procedures that required general anesthesia must be completed at least 2 weeks before first study intervention administration.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Toll Free Number",
                    "role": "CONTACT",
                    "phone": "1-888-577-8839",
                    "email": "Trialsites@merck.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Merck Sharp & Dohme LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "St. Vincent Frontier Cancer Center-Research ( Site 0105)",
                    "status": "RECRUITING",
                    "city": "Billings",
                    "state": "Montana",
                    "zip": "59102",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "406-238-6290"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.78329,
                        "lon": -108.50069
                    }
                },
                {
                    "facility": "Clinica Universidad Catolica del Maule-Oncology ( Site 0500)",
                    "status": "RECRUITING",
                    "city": "Talca",
                    "state": "Maule",
                    "zip": "3465584",
                    "country": "Chile",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "56981340385"
                        }
                    ],
                    "geoPoint": {
                        "lat": -35.4264,
                        "lon": -71.65542
                    }
                },
                {
                    "facility": "FALP-UIDO ( Site 0501)",
                    "status": "RECRUITING",
                    "city": "Santiago",
                    "state": "Region M. De Santiago",
                    "zip": "7500921",
                    "country": "Chile",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "56224457254"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.45694,
                        "lon": -70.64827
                    }
                },
                {
                    "facility": "Centro de Oncolog\u00eda de Precisi\u00f3n-Oncology ( Site 0502)",
                    "status": "RECRUITING",
                    "city": "Santiago",
                    "state": "Region M. De Santiago",
                    "zip": "7560908",
                    "country": "Chile",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+56991612199"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.45694,
                        "lon": -70.64827
                    }
                },
                {
                    "facility": "Chonnam National University Hwasun Hospital-Pulmonology ( Site 3604)",
                    "status": "RECRUITING",
                    "city": "Hwasun",
                    "state": "Jeonranamdo",
                    "zip": "58128",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+82613797614"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.06125,
                        "lon": 126.98746
                    }
                },
                {
                    "facility": "Pusan National University Yangsan Hospital-Lung Cancer Clinic ( Site 3603)",
                    "status": "RECRUITING",
                    "city": "Yangsan",
                    "state": "Kyongsangnam-do",
                    "zip": "50612",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "82-10-2870-9389"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.34199,
                        "lon": 129.03358
                    }
                },
                {
                    "facility": "Korea University Guro Hospital ( Site 3601)",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "08308",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "821022179216"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Communal Nonprofit Enterprise \"Clinical Center of Oncology, Hematology, Transplantology and Palliati",
                    "status": "RECRUITING",
                    "city": "Cherkasy",
                    "state": "Cherkaska Oblast",
                    "zip": "18009",
                    "country": "Ukraine",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "380963078884"
                        }
                    ],
                    "geoPoint": {
                        "lat": 49.42854,
                        "lon": 32.06207
                    }
                },
                {
                    "facility": "Regional Municipal Non-profit Enterprise \"Bukovinian Clinica-structural unit of the clinical trials",
                    "status": "RECRUITING",
                    "city": "Chernivtsi",
                    "state": "Chernivetska Oblast",
                    "zip": "58013",
                    "country": "Ukraine",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "380955077568"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.29149,
                        "lon": 25.94034
                    }
                },
                {
                    "facility": "Medical Center \"Mriya Med-Service\"-Clinical Research Department ( Site 2215)",
                    "status": "RECRUITING",
                    "city": "Kryvyi Rih",
                    "state": "Dnipropetrovska Oblast",
                    "zip": "50000",
                    "country": "Ukraine",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "380973567855"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.90966,
                        "lon": 33.38044
                    }
                },
                {
                    "facility": "Communal Non-Commercial Enterprise \"Prykarpatski Clinical On-Surgery department #2 ( Site 2202)",
                    "status": "RECRUITING",
                    "city": "Ivano-Frankivsk",
                    "state": "Ivano-Frankivska Oblast",
                    "zip": "76018",
                    "country": "Ukraine",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "380978411455"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.9215,
                        "lon": 24.70972
                    }
                },
                {
                    "facility": "Kirovohrad Regional Oncology Center-Chemotherapy department ( Site 2204)",
                    "status": "RECRUITING",
                    "city": "Kropyvnytskyi",
                    "state": "Kirovohradska Oblast",
                    "zip": "25011",
                    "country": "Ukraine",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "380508412400"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.5132,
                        "lon": 32.2597
                    }
                },
                {
                    "facility": "Medical Center \"MedOffice Group\" ( Site 2219)",
                    "status": "RECRUITING",
                    "city": "Kiev",
                    "state": "Kyivska Oblast",
                    "zip": "03022",
                    "country": "Ukraine",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "380503858689"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.45466,
                        "lon": 30.5238
                    }
                },
                {
                    "facility": "Municipal non-profit enterprise \"Lviv Territorial Medical Union \"Multidisciplinary Clinical Hospital",
                    "status": "RECRUITING",
                    "city": "Lviv",
                    "state": "Lvivska Oblast",
                    "zip": "79000",
                    "country": "Ukraine",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+380677724757"
                        }
                    ],
                    "geoPoint": {
                        "lat": 49.83826,
                        "lon": 24.02324
                    }
                },
                {
                    "facility": "Rivne Regional Clinical Hospital ( Site 2205)",
                    "status": "RECRUITING",
                    "city": "Rivne",
                    "state": "Rivnenska Oblast",
                    "zip": "33007",
                    "country": "Ukraine",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "380503802915"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.62308,
                        "lon": 26.22743
                    }
                },
                {
                    "facility": "Communal Noncommercial Enterprise \"Podillia Regional Oncolog-Cardiothoracic department ( Site 2211)",
                    "status": "RECRUITING",
                    "city": "Vinnytsia",
                    "state": "Vinnytska Oblast",
                    "zip": "21029",
                    "country": "Ukraine",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "380953105783"
                        }
                    ],
                    "geoPoint": {
                        "lat": 49.23278,
                        "lon": 28.48097
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Merck Clinical Trials Information",
                    "url": "https://www.merckclinicaltrials.com/"
                },
                {
                    "label": "Plain Language Summary",
                    "url": "https://trialstransparency.merckclinicaltrials.com/Study.aspx?id=1084-004&&kw=1084-004"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf",
            "url": "http://engagezone.msd.com/ds_documentation.php"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Non-small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "asFound": "Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15327",
                    "name": "Sarcoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M6845",
                    "name": "Death",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "T5284",
                    "name": "Soft Tissue Sarcoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}